Intravenous ferric derisomaltose for the treatment of iron deficiency anemia

Michael Auerbach, David Henry, Thomas G. DeLoughery

    Research output: Contribution to journalReview articlepeer-review

    Abstract

    Intravenous (IV) iron is the therapy of choice when oral iron is ineffective or poorly tolerated, yet use has been limited by fears of hypersensitivity reactions (HSRs). Newer formulations that bind iron more tightly and release it more slowly have made the risk of serious or severe HSRs very low. One such formulation, ferric derisomaltose, has been approved in the United States for delivery of 1000 mg iron in a single IV infusion. Ferric derisomaltose rapidly repletes iron parameters with low rates of serious or severe HSRs. Single-infusion iron repletion offers convenience, eliminates adherence concerns, and reduces healthcare resource utilization.

    Original languageEnglish (US)
    Pages (from-to)727-734
    Number of pages8
    JournalAmerican Journal of Hematology
    Volume96
    Issue number6
    DOIs
    StatePublished - Jun 1 2021

    ASJC Scopus subject areas

    • Hematology

    Fingerprint

    Dive into the research topics of 'Intravenous ferric derisomaltose for the treatment of iron deficiency anemia'. Together they form a unique fingerprint.

    Cite this